Cellectis - CLLS STOCK NEWS

Cellectis S.A. has launched an underwritten global offering of 8,800,000 American Depositary Shares (ADS) at $2.50 each, aimed at raising approximately $20.2 million post-expenses. The proceeds are intended for clinical development of UCART therapies and general corporate purposes. The offering, scheduled to close on February 7, 2023, will lead to a dilution of approximately 16.2% of existing shares. The offered ADSs will commence trading on the Nasdaq Global Market. Jefferies and Barclays are the joint book-running managers for the offering, which is backed by a 30-day option for underwriters to purchase additional shares. These steps follow Cellectis' strategy to fund its cell and gene therapy advancements.

Cellectis, a clinical-stage biotechnology company focused on gene-editing therapies, has launched a global offering of $22 million in American Depositary Shares (ADS). Each ADS represents one ordinary share, with a nominal value of €0.05. The offering includes a public offering in the U.S. and a private placement for qualified investors in other countries. Proceeds will support the clinical development of several product candidates and general corporate purposes. The offering size and price will be determined through an accelerated bookbuilding process. Cellectis has been granted the option for underwriters to purchase an additional 15% of the offering.

Cellectis (NASDAQ: CLLS) announced an amendment to the financial terms of a $20 million convertible note with Cytovia Therapeutics. The amended note allows for automatic conversion into Cytovia's common stock during specific fundamental transactions and also grants Cellectis conversion options upon financing or company sale. Key changes include an increase in the interest rate to 10% per annum, a requirement for 50% repayment by April 30, 2023, and an extension of the final maturity date to June 30, 2023. Cellectis leverages its gene-editing platform for innovative cell and gene therapies targeting difficult medical conditions.

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) announced the merger of Calyxt (NASDAQ: CLXT) and Cibus Global. The all-stock transaction will merge these agriculture-based gene editing companies, combining their resources for trait development and plant breeding. Cellectis holds a 49.1% equity interest in Calyxt, expected to decrease to approximately 2.5% post-merger. The merger requires approvals from Calyxt’s stockholders and Cibus’ members, along with necessary regulatory approvals, with closing anticipated in Q2 2023. The merger aims to leverage the strengths of both companies in gene editing technologies.

The merger between Calyxt and Cibus aims to create a leading entity in precision gene editing and sustainable agriculture. Under the all-stock deal, Calyxt shareholders will retain approximately 5% of the new company, which will operate under the name Cibus Inc. Key applications include enhancing productivity traits in seeds and developing renewable low-carbon ingredients. The merger supports a strong collaboration pipeline with major seed companies, with three productivity traits expected to launch in early 2023. Both companies anticipate significant regulatory developments that could enhance market opportunities.

Cellectis has announced its intention to conduct an at-the-market offering (ATM) of up to $60 million in American Depositary Shares (ADS) as of January 4, 2023. This program is set to run until July 6, 2025, unless terminated earlier. The funds raised will primarily support the clinical development of its gene therapies, including UCART 123 and others. The potential dilution for existing shareholders is estimated at approximately 23.04%. Jefferies LLC will act as the sales agent, with shares issued without preferential rights for existing shareholders.

Cellectis (Nasdaq: CLLS) has entered into a collaboration with Primera Therapeutics, facilitated by Mayflower Bioventures. The partnership aims to develop gene editing therapies targeting mitochondrial diseases, which currently lack effective treatments. Primera will leverage its innovations from the Mayo Clinic to address mutations in mitochondrial DNA. Cellectis will acquire a 19% stake in Primera and may earn up to $750 million in milestone payments as well as royalties. This collaboration emphasizes Cellectis’ commitment to addressing unmet medical needs through gene editing.

Cellectis has secured a €40 million credit facility from the European Investment Bank to advance its UCART product pipeline. The facility is structured in three tranches: €20 million for Tranche A, €15 million for Tranche B, and €5 million for Tranche C, each with specific conditions for disbursement. This financing aims to support the development of allogeneic CAR T-cell therapies targeting severe unmet medical needs. The facility is designed to be minimally dilutive for shareholders, carrying a decreasing fixed interest rate, capitalized annually.

Cellectis announced a significant milestone as the first patient was dosed in the U.S. with its UCART22 product candidate, completing the 28-day Dose Limiting Toxicity (DLT) observation period without complications. This achievement underscores Cellectis' in-house manufacturing capabilities, which enhance efficiency in clinical trials for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The company aims to provide timely treatment, controlling the entire process from research and development to clinical manufacturing.